Pancreatic cancer has always carried a kind of weight that no one really wants to put into words. It’s one of those diagnoses that usually comes in late, moves fast, and leaves very little room for options. Unlike some other cancers where early detection can completely change the outcome, this one often stays quiet until it has already spread. That’s part of the reason it has stayed so deadly for so long, and why even small improvements in treatment tend to feel like major news in the oncology world.
Pancreatic cancer is also a relatively rare cancer compared to others, however the impact is anything but small. In the United States alone, over 60,000 people are diagnosed every year, and globally it continues to rank among the top causes of cancer-related deaths. The survival numbers have historically been harsh; only a small percentage of patients make it past a few years, especially in advanced stages. A big part of the challenge is that symptoms like weight loss, jaundice, abdominal pain or fatigue don’t appear early enough to catch it in time. By the time it’s diagnosed, doctors are usually dealing with an advanced or metastatic disease, which limits how far standard treatment can go.
That’s exactly why the new experimental drug daraxonrasib is getting so much attention
Daraxsonrasib is an oral pill being tested in large international phase 3 trials involving around 500 patients who had already undergone earlier treatment. Instead of using traditional chemotherapy alone, this drug targets one of the main genetic drivers behind pancreatic cancer, mutations in the KRAS gene, which are present in more than 90% of cases and basically act like a stuck “on switch” that keeps cancer cells growing.
For years, KRAS was considered almost impossible to target directly, which is why pancreatic cancer treatment didn’t change much for decades. Daraxonrasib changes that approach. Rather than attacking the gene in a traditional way, it works inside the cell to shut down the abnormal signalling pathway that KRAS triggers, essentially cutting off the message that tells cancer cells to keep multiplying.
The results from the trial have been hard to ignore. Here’s why
- Patients taking the drug lived a median of about 13.2 months compared to roughly 6.6 months with chemotherapy, which is nearly double the survival time in a disease where even a few extra months matter.
- The therapy also reduced the risk of death by around 60%, and delayed disease progression compared to standard treatment.
- Patients also tended to stay on treatment longer and reported better quality of life overall, even though side effects like skin rash, nausea, and digestive issues were still common.
What makes these findings even more significant is not just the numbers, but what it represents. The study, known as the RASolute 302 trial, is one of the first large-scale demonstrations that targeting KRAS-driven pancreatic cancer can actually work in a meaningful clinical way. It has already been published in a major medical journal and is now under regulatory review, with fast-track consideration likely because of how strong the results are.
If approved, daraxonrasib could become one of the first true targeted therapies for advanced pancreatic cancer, especially for patients whose tumours carry KRAS mutations. It doesn’t mean the disease is suddenly easy to treat, but it does shift the tone a little—from something that has felt almost unchangeable for years to something where real progress is finally starting to show up.
Sources: The Conversation, BBC, CBC, The New England Journal of Medicine, Pancreatic Cancer Action Network
